top of page
The Professional Network for Healthcare Experts
argenx agrees to acquire Unnatural Products for up to $1.15 billion to expand peptide drug discovery
argenx has agreed to acquire macrocyclic peptide specialist Unnatural Products in a transaction worth up to $1.15 billion, combining a substantial upfront payment with development-dependent milestones to expand beyond antibody therapeutics.
nuaxia
23 hours ago2 min read
Lilly agrees acquisition of Merida Biosciences in deal worth up to $2.875bn
Lilly’s planned acquisition of Merida Biosciences adds an antibody-engineering platform designed to selectively remove disease-causing antibodies while preserving normal immune function.
nuaxia
Sep 12 min read
bottom of page